If you or someone you know suffers from uncontrolled moderate to severe eosinophilic asthma, there's a new treatment being tested called KT-621. This Phase 2b study is designed to see how well KT-621 works and how safe it is for patients. Eosinophilic asthma is a type of asthma that can be particularly difficult to manage, and finding effective treatments is crucial for improving quality of life. The study will measure how KT-621 affects lung function, specifically looking at a measurement called FEV1, which indicates how much air you can forcefully exhale in one second. With 264 participants expected to enroll, this research could provide valuable insights into a new option for those who struggle to control their asthma symptoms. If successful, KT-621 might offer hope for better management of this challenging condition.
Can KT-621 help people with severe asthma breathe easier?
Plain Language Summary
What this means for you:
KT-621 is being tested as a potential new treatment for severe eosinophilic asthma. What this means for you:
KT-621 is being tested as a potential new treatment for severe eosinophilic asthma. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Eosinophilic Asthma
Intervention(s): KT-621 (DRUG), Placebo (OTHER)
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.
Primary Outcome(s): Change from baseline in pre-bronchodilator FEV1
Enrollment: 264 (ESTIMATED)
Lead Sponsor: Kymera Therapeutics, Inc.
Start: 2026-01-28 | Primary Completion: 2027-12